GEO series

p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (RPMI8226_KB528_timeseries)

GSE274845 Homo sapiens (human) RNA-seq (gene expression) 15 samples Submitted 2025/10/20 Platform GPL34284

At a glance

RNA-seq (gene expression) · human · 15 samples

What it is: RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism: Homo sapiens (human)
Samples: 15 samples: 5 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
Data you can get: A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Paper: Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple MyelomaCancer research · 2026

Summary (written by the submitters)

The oncogenic transcription factor (TF) IRF4 is a universal multiple myeloma (MM) dependency that remains undrugged owing to its disordered structure. Using transcriptional regulatory network (TRN) mapping, an unbiased multi-omic approach to nominate druggable TF cofactors, we identified the chromatin coactivator lysine acetyltransferase (KAT) p300 as a key IRF4 partner.

Read the full summary ↓

We developed KB528, a highly selective p300 KAT inhibitor to explore the regulatory relationship between IRF4 and p300. Instead of broadly inhibiting transcription, partial p300 KAT inhibition selectively downregulates IRF4 and its downstream gene expression program leading to apoptosis selectively in MM cells. IRF4 dependency is a hallmark of MM that exists downstream of existing MM therapies. Consequently, p300 KAT inhibition exhibits strong antiproliferative activity ex vivo and in vivo as a single agent as well as in combination regimens in treatment refractory models. p300 KAT inhibition is well-tolerated in vivo motivating further clinical development in MM.

Published in

Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma

Lenoir WF, McKeown MR, Giorgetti G et al. · Cancer research 2026 · PMID 41248492 · doi:10.1158/0008-5472.CAN-25-3440

This dataset

Open GSE274845 in finder → Find more human RNA-seq datasets →

Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓

2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE274845_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓

3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1148171 and SRA study SRP526433. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗ Paper (PMID 41248492) ↗

Study design

5 conditions, mostly in triplicate

RPMI8226_DMSO ×3 RPMI8226_KB528_1h ×3 RPMI8226_KB528_3h ×3 RPMI8226_KB528_6h ×3 RPMI8226_KB528_24h ×3

Supports a between-group comparison across 15 samples.

How we read this: 5 replicated groups read from 15 sample titles; they account for 15 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.

Samples in this study

GSM8459115 RPMI8226_DMSO_1 RPMI8226_DMSO
GSM8459116 RPMI8226_DMSO_2 RPMI8226_DMSO
GSM8459117 RPMI8226_DMSO_3 RPMI8226_DMSO
GSM8459118 RPMI8226_KB528_1hr_1 RPMI8226_KB528_1h
GSM8459119 RPMI8226_KB528_1hr_2 RPMI8226_KB528_1h
GSM8459120 RPMI8226_KB528_1hr_3 RPMI8226_KB528_1h
GSM8459121 RPMI8226_KB528_3hr_1 RPMI8226_KB528_3h
GSM8459122 RPMI8226_KB528_3hr_2 RPMI8226_KB528_3h
GSM8459123 RPMI8226_KB528_3hr_3 RPMI8226_KB528_3h
GSM8459124 RPMI8226_KB528_6hr_1 RPMI8226_KB528_6h
GSM8459125 RPMI8226_KB528_6hr_2 RPMI8226_KB528_6h
GSM8459126 RPMI8226_KB528_6hr_3 RPMI8226_KB528_6h
GSM8459127 RPMI8226_KB528_24hr_1 RPMI8226_KB528_24h
GSM8459128 RPMI8226_KB528_24hr_2 RPMI8226_KB528_24h
GSM8459129 RPMI8226_KB528_24hr_3 RPMI8226_KB528_24h

Datasets on a similar topic

GSE274841 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (MM1S_KB528_timeseries) 15 samples shares kb528, p300, irf4, selectively, inhibition, timeseries, catalytic
GSE274843 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (PBMC_KB528_timeseries) 15 samples shares kb528, p300, irf4, selectively, inhibition, timeseries, catalytic
GSE274593 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (MM1S_ChIP_KB528) 44 samples shares kb528, p300, irf4, selectively, inhibition, catalytic
GSE274846 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (MM1S_SOC) 45 samples shares p300, irf4, selectively, inhibition, catalytic
GSE274597 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (IRF4KD) 24 samples shares p300, irf4, selectively, inhibition, catalytic
GSE274596 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (DF_pt) 6 samples shares p300, irf4, selectively, inhibition, catalytic
GSE307536 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma 164 samples shares p300, irf4, selectively, inhibition, catalytic
GSE304253 Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML. [SLAM-Seq] 35 samples shares p300, inhibition, catalytic

Search all human RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.